Manages central (cranial) diabetes insipidus. ANDA 204751, held by Sagent Pharmaceuticals. Desmopressin Acetate.
As of Nov 20, 2026, ANDA 204751 (Desmopressin Acetate), held by Sagent Pharmaceuticals, was first approved by FDA on Aug 22, 2017, with 2 approved supplements and 0 published complete response letters.
Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 22, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desmopressin Acetate0.004MG/ML · injectable;injection | Desmopressin Acetate | Rx |
| Mar 21, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 25, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 22, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters